What is Tango Therapeutics's deferred revenue?

Tango Therapeutics (TNGX) reported deferred revenue of $0 in Q4 2025.

How has Tango Therapeutics's deferred revenue changed year-over-year?

Tango Therapeutics's deferred revenue increased by 100.0% year-over-year, from -$4.12M to $0.

What is the long-term trend for Tango Therapeutics's deferred revenue?

Over 3 years (2022 to 2025), Tango Therapeutics's deferred revenue has grown at a 54.7% compound annual growth rate (CAGR), from -$16.86M to -$62.38M.

Tango Therapeutics TNGX Deferred Revenue

Deferred Revenue at other companies

UnitedHealth GroupUNH

$20M+300%

AirbnbABNB

$988M-10.6%

FAN

Diamondback EnergyFANG

$70M-16.7%

Cadence Design SystemsCDNS

$20.42M+242%

MPLXMPLX

-$1M+91.7%

CortevaCTVA

-$2.28B0.0%

Other financials

Income statement

See full

Revenue--100%

Operating income-$48.8M-14.7%

Net income-$45.5M-14.1%

EPS (diluted)-$0.32+11.1%

Balance sheet

See full

Cash & equivalents$160.0M+162%

Total debt$32.8M-11.3%

Total equity$391.5M+135%

Total assets$435.8M+58.9%

Cash flow

See full

Operating cash flow-$44.4M-6.4%

CapEx-$2.0K-104%

Free cash flow-$44.4M-6.3%

Valuation

See full

Market cap$4.55B+1,915%

Profitability

See full

Operating margin-206.2%-61.0pp

Net margin-188.2%-55.4pp

FCF margin-250.1%-49.4pp

Returns & leverage

See full

Return on equity-38.4%-10.5pp

Debt / equity0.1×-0.1×

Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredRevenue.

The official record: Tango Therapeutics’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tango Therapeutics's deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Tango Therapeutics's deferred revenue?: Tango Therapeutics (TNGX) reported deferred revenue of $0 in Q4 2025.
How has Tango Therapeutics's deferred revenue changed year-over-year?: Tango Therapeutics's deferred revenue increased by 100.0% year-over-year, from -$4.12M to $0.
What is the long-term trend for Tango Therapeutics's deferred revenue?: Over 3 years (2022 to 2025), Tango Therapeutics's deferred revenue has grown at a 54.7% compound annual growth rate (CAGR), from -$16.86M to -$62.38M.